Category Archives: Cell Therapy

Abbott Animal Hospital - Rehoboth, MA - Bubba before stem cell therapy Bubba, a 2 1/2 year old English Bulldog was born with hip dysplasia and has been suffering with this disease since birth. His owner Bob Cook of Taunton has been seeking out alternative treatment options for his condition. Abbott Animal Hospital is the first veterinary hospital which offers FDA approved stem cell therapy for any osteoarthritis patients, both cats and dogs. Mr. Cook contacted Dr. Ashraf Gomaa and elected to pursue this new advanced therapy. Check out abbottanimalhospital.com or like us on facebook http://www.facebook.com/abbotthospital for more details! By: Ashraf Gomaa … Continue reading →

OMICS Group Cell Therapy-2012 Opeing Ceremony OMICS Group Cell Therapy-2012 Opeing Ceremony By: omicsvideos … Continue reading →

Head Injury Improves After Stem Cell Therapy Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com By: neurogenbsi … Continue reading →

ALLENDALE, N.J. and OXFORD, United Kingdom, Jan. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286). PCT's services will include the transfer and qualification of Adaptimmune's manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT's facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune's clinical trials. Adaptimmune develops products containing unique engineered T cell receptors for the treatment of cancer and infectious diseases. The company has a research base in Oxford, UK and a clinical base in Philadelphia, Pennsylvania. In December, at the American Society of Hematology conference, Adaptimmune announced encouraging preliminary results from its expanded multiple myeloma trial. Related trials in melanoma and sarcoma are also recruiting patients. PCT is an internationally recognized contract development and manufacturing organization with facilities in Allendale, New Jersey and Mountain View, California. The company has expertise in GMP manufacture for … Continue reading →

ALLENDALE, N.J. and OXFORD, United Kingdom, Jan. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286). PCT's services will include the transfer and qualification of Adaptimmune's manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT's facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune's clinical trials. Adaptimmune develops products containing unique engineered T cell receptors for the treatment of cancer and infectious diseases. The company has a research base in Oxford, UK and a clinical base in Philadelphia, Pennsylvania. In December, at the American Society of Hematology conference, Adaptimmune announced encouraging preliminary results from its expanded multiple myeloma trial. Related trials in melanoma and sarcoma are also recruiting patients. PCT is an internationally recognized contract development and manufacturing organization with facilities in Allendale, New Jersey and Mountain View, California. The company has expertise in GMP manufacture for … Continue reading →

MFIII Swiss Cell Therapy for Regeneration, Rejuvenation and Revitalisation MFIII Swiss Cell Therapy for Regeneration, Rejuvenation and Revitalisation By: Vina Higgs … Continue reading →

Ovation Cell Therapy: Sell an Invention This is for bioligy By: Nucleusforpres … Continue reading →

MOUNTAIN VIEW, Calif., Jan. 14, 2013 /PRNewswire/ --SanBio Inc. today announced the successful enrollment of the second dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 12 patients, of a planned total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University, the University of Pittsburgh and Northwestern University. No safety concerns have been attributed to the cell therapy product. For details regarding this clinical trial, please refer to http://www.strokeclinicaltrial.org. SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "The successful completion of the first two dose cohorts of this pioneering clinical trial is a clear indication of the dedication and professionalism of the entire team," said Keita Mori, SanBio CEO. SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy are also being tested. "We are pleased with the safety findings of the … Continue reading →

Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3 Stem cell therapy for osteoarthritis using adipose (fat) stem cell. Case study of 76 year-old man with osteoarthritis in his knees. Stromal vasular fraction treatment statistics including side effects collected over 800 infusions. Stem cell treatments for sports injuries and why pro sports stars are seeking treatment. Case study of a professional dancer with knee and neck problems who returned to competition after stem cell treatment in Panama. By: cellmedicine … Continue reading →

Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3 Stem cell therapy for osteoarthritis using adipose (fat) stem cell. Case study of 76 year-old man with osteoarthritis in his knees. Stromal vasular fraction treatment statistics including side effects collected over 800 infusions. Stem cell treatments for sports injuries and why pro sports stars are seeking treatment. Case study of a professional dancer with knee and neck problems who returned to competition after stem cell treatment in Panama. By: cellmedicine … Continue reading →